<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Brain Tumor on Just for your understanding</title>
    <link>/categories/brain-tumor/</link>
    <description>Recent content in Brain Tumor on Just for your understanding</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 21 Jul 2018 00:00:00 +0000</lastBuildDate>
    
	<atom:link href="/categories/brain-tumor/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>Cell apoptosis signaling pathway</title>
      <link>/post/2018/07/21/cell-apoptosis-signaling-pathway/</link>
      <pubDate>Sat, 21 Jul 2018 00:00:00 +0000</pubDate>
      
      <guid>/post/2018/07/21/cell-apoptosis-signaling-pathway/</guid>
      <description>Background I reviewed several manuscripts titled liket &amp;ldquo;XX promotes oxidative stress and induces apoptosis in YY cells&amp;rdquo;.
Here, &amp;ldquo;XX&amp;rdquo; can be any chemical from nature product or synthezed in the lab. &amp;ldquo;YY&amp;rdquo; can be caner cells, nenron cells and various cells. They may be cell lines or primary cells. By combination, hundreds of paper can be produced. How do you evaluate them in the perspective of basic reserch or drug development?</description>
    </item>
    
    <item>
      <title>Why cancer happens?</title>
      <link>/post/2018/07/15/why-cancer-happens/</link>
      <pubDate>Sun, 15 Jul 2018 00:00:00 +0000</pubDate>
      
      <guid>/post/2018/07/15/why-cancer-happens/</guid>
      <description>The nature of cancer is abnormal proliferation of cells made of our organ, tissue and body.</description>
    </item>
    
    <item>
      <title>Neuro-Oncology</title>
      <link>/post/2018/07/03/neuro-oncology/</link>
      <pubDate>Tue, 03 Jul 2018 00:00:00 +0000</pubDate>
      
      <guid>/post/2018/07/03/neuro-oncology/</guid>
      <description>Neuro Oncology It is the officical journal of the Society for Neuro-Oncology and published monthly from Jan.2010.
Kenneth Aldape is the interim editor-in-chief. His research area is genomic and epigenomic alterations in brain tumors, including glioma and meningioma. His valuable contribution to brain tumor is (1) (2) Reference:
 </description>
    </item>
    
  </channel>
</rss>